Berlin, August 13, 2024 – Eckert
Telix’s ProstACT GLOBAL study is investigating the benefits and harms of rosopatamab tetraxetan lutetium (Lu 177), a radiolabeled antibody-drug conjugate (rADC), in adult men with prostate-specific membrane antigen (PSMA)-positive prostate cancer. , in combination with care.
“We are pleased to further expand our successful and long-standing collaboration with Telix,” said Dr. Harald Hasselmann, CEO of Eckert.
This collaboration marks a milestone in both companies’ ongoing efforts to advance cutting-edge responses in the field of radiopharmaceuticals. Eckert